ID: ALA5278919

Max Phase: Preclinical

Molecular Formula: C33H28F2N5O4P

Molecular Weight: 627.59

Representations

Canonical SMILES:  Cc1noc(-c2ccc(C(C/C=C/c3ccccc3)(Cc3ccc(C(F)(F)P(=O)(O)O)cc3)n3nnc4ccccc43)cc2)n1

Standard InChI:  InChI=1S/C33H28F2N5O4P/c1-23-36-31(44-38-23)26-15-19-27(20-16-26)32(21-7-10-24-8-3-2-4-9-24,40-30-12-6-5-11-29(30)37-39-40)22-25-13-17-28(18-14-25)33(34,35)45(41,42)43/h2-20H,21-22H2,1H3,(H2,41,42,43)/b10-7+

Standard InChI Key:  AWPQDTIETWJPSM-JXMROGBWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 627.59

Molecular Weight (Monoisotopic): 627.1847

AlogP: 7.11

#Rotatable Bonds: 10

Polar Surface Area: 127.16

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 0.76

CX Basic pKa: 0.19

CX LogP: 6.63

CX LogD: 4.55

Aromatic Rings: 6

Heavy Atoms: 45

QED Weighted: 0.15

Np Likeness Score: -0.84

References

1. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A..  (2020)  Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.,  207  [PMID:32871344] [10.1016/j.ejmech.2020.112742]

Source

Source(1):

• Scientific Literature